

The MPT Product Candidate Pipeline by Delivery Method

Product Name	Product Developer	Stage of Development	Indications
Intravaginal Rings (IVRs)			
Dapivirine + Pritelivir + Levonorgestrel 3D Printed IVR	University of North Carolina, Chapel Hill	Early Preclinical	HIV, Unintended Pregnancy, and HSV-2
Islatravir (EFdA) + Etonogestrel/Ethinyl Estradiol 3D Printed IVR	University of North Carolina, Chapel Hill	Early Preclinical	HIV and Unintended Pregnancy
Novel mAb contraceptive + Tenofovir Disoproxil Fumarate (TDF) IVR	Oak Crest Institute of Science, Univ. of North Carolina, Chapel Hill	Early Preclinical	HIV and Unintended Pregnancy
90-day Pod-type Etonogestrel/Ethinyl Estradiol/QGriffithsin (EEQ) IVR	Population Council, Oak Crest Institute of Science	Early Preclinical	HIV and Unintended Pregnancy
CZL Ring	Population Council, Queen's University Belfast, Weill Cornell Medical College	Early Preclinical	HIV, Unintended Pregnancy, HSV-2, Gonorrhea, Chlamydia, and BV
Non-ARV/Non-Hormonal Multi-Purpose Vaginal Ring	Oak Crest Institute of Science	Advanced Preclinical	HSV and Unintended Pregnancy
Dapivirine + Levonorgestrel IVR	Population Council	Phase I Clinical Trial	HIV and Unintended Pregnancy
Gels (Vaginal)			
PPCM-GEL	Yaso Therapeutics	Fast Track SBIR	Unintended Pregnancy, HSV-2, Gonorrhea
Acetic Acid Thermoreversible Gel	National Research Institute for Family Planning, China	Preclinical – (Pre2)	Unintended Pregnancy and STIs
Trifunctional TNG Gel	Beijing Institute of Geriatrics, North Carolina State University	Pre-Clinical	Unintended Pregnancy and STIs
Fast-dissolving Inserts (FDIs) (Vaginal & Rectal)			
Griffithsin (GRFT) Fast-Dissolving Insert (FDI)	SwiftPharma	Pre-formulation	HIV, HSV-2, and HPV
Non-hormonal Contraceptive MPT Containing Q-Griffithsin (QGRFT)	Population Council	Early Preclinical	HIV, Pregnancy, HSV-2, BV, Chlamydia, and Gonorrhea
TAF)/EVG Topical Insert	CONRAD	Phase II Clinical Trial	HIV and HSV-2
TAF/Elvitegravir/Doxycycline Topical Insert	CONRAD	Ready for IND-Enabling and Clinical-Phase I	HIV and HSV-2, bacterial STIs including chlamydia
Intrauterine Devices (IUDs)			
Low-profile copper IUD	University of Washington	Early Preclinical	HIV and Unintended Pregnancy

The MPT Product Candidate Pipeline by Delivery Method (continued)

Product Name	Product Developer	Stage of Development	Indications
Films (Vaginal)			
Monoclonal Antibody ER Film	Magee-Women's Research Inst. & Fndn., University of Pittsburgh	Early Preclinical	HIV, HSV-2, and Unintended Pregnancy
Progestin Intravaginal Film	Magee-Women's Research Inst. & Fndn., University of Pittsburgh	Early Preclinical	HIV and Unintended Pregnancy
Dapivirine/Levonorgestrel Extended-Release Monthly Film	Magee-Women's Research Inst. & Fndn., University of Pittsburgh	Early Preclinical	HIV and Unintended Pregnancy
Tenofovir + Levonorgestrel Vaginal Film	University of Lagos	Pre-clinical	HIV, other STIs and Unintended Pregnancy
Implants			
Pellet Implant with Levonorgestrel	CONRAD	Early Preclinical	HIV and Unintended Pregnancy
Long-acting refillable nanofluidic implant (NanoMPI)- SC	University of Washington Methodist Hospital Research Institute (HMRI)	Early Preclinical	HIV and Unintended Pregnancy
Injectables			
Cabotegravir/Levonorgestrel Long-Acting MPT Injectable	CONRAD	Advanced Preclinical	HIV and Unintended Pregnancy
Injectable In-situ Forming Implants			
Ultra-Long-Acting MPT In-situ Forming Implant (ISFI)	University of North Carolina, Chapel Hill	Early Preclinical	HIV and Unintended Pregnancy
Oral Tablets			
Dual Prevention Pill (DPP)/TELE	Viatis	Submitted for WHO PQ approval	HIV and Unintended Pregnancy
Other			
MPT Microarray Patch (MAP)	PATH; Queen's University Belfast	Early Preclinical	HIV, Unintended Pregnancy
Non-Hormonal Electrospun Mesh MPT	University of Lagos	Discovery & Early Development	Unintended Pregnancy and STIs